Compare Royal Caribbean Cruises Ltd (RCL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $285.5 (market cap $76.75B), while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 47.1× Recursion Pharmaceuticals Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RCL | RXRX | |
|---|---|---|
Market Cap | $76.75B | $1.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $365.84 | $6.79 |
52-Week Low | $246.71 | $2.84 |
Enterprise Value | $98.03B | $1.05B |
Dividend Yield | 1.75% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
